SUMMARY: We measured bone mineral densities in 28 intracranial germ cell tumor long-term survivors. There was the high prevalence of osteoporosis and osteopenia, 25.0% and 42.9%, respectively, and three additional risk factors, male sex, a low lean mass, and adult growth hormone replacement, were identified. INTRODUCTION: Intracranial germ cell tumor long-term survivors (iGCTLS) have many risk factors for osteoporosis, including irradiation from cancer therapy and multiple hormone deficiencies. However, no study of bone mineral density (BMD) has been conducted in iGCTLS because these tumors are rare. The aims of this study were to evaluate the prevalence of osteoporosis and to identify risk factors associated with reduced bone mass in iGCTLS. METHODS: We evaluated BMD and body composition of 28 iGCTLS (10.9 ± 5.2 years after cancer treatment; 13 males) using dual-energy X-ray absorptiometry. To determine risk factors, we analyzed the medical history, including the nature of the tumor, treatment modality, endocrine status, hormone replacement therapy, lifestyle, and biochemical parameters. RESULTS: Twenty-five percent of iGCTLS were diagnosed with osteoporosis and 42.9% with osteopenia. Most males (92.3%) had low BMD. Lean mass (LM) was positively correlated with BMD in all regions of interest, and the starting age of adult growth hormone (GH) replacement was negatively correlated with the BMD Z-score at the femur neck. In logistic regression analysis, male sex and low LM were related to low BMD. CONCLUSIONS: The iGCTLS had a high prevalence of low BMD. We found that male sex, low LM, and delayed start of adult GH replacement were risk factors for osteoporosis. Therefore, the BMD of all iGCTLS should be evaluated, and if it is low, proper management should be started early.
SUMMARY: We measured bone mineral densities in 28 intracranial germ cell tumor long-term survivors. There was the high prevalence of osteoporosis and osteopenia, 25.0% and 42.9%, respectively, and three additional risk factors, male sex, a low lean mass, and adult growth hormone replacement, were identified. INTRODUCTION: Intracranial germ cell tumor long-term survivors (iGCTLS) have many risk factors for osteoporosis, including irradiation from cancer therapy and multiple hormone deficiencies. However, no study of bone mineral density (BMD) has been conducted in iGCTLS because these tumors are rare. The aims of this study were to evaluate the prevalence of osteoporosis and to identify risk factors associated with reduced bone mass in iGCTLS. METHODS: We evaluated BMD and body composition of 28 iGCTLS (10.9 ± 5.2 years after cancer treatment; 13 males) using dual-energy X-ray absorptiometry. To determine risk factors, we analyzed the medical history, including the nature of the tumor, treatment modality, endocrine status, hormone replacement therapy, lifestyle, and biochemical parameters. RESULTS: Twenty-five percent of iGCTLS were diagnosed with osteoporosis and 42.9% with osteopenia. Most males (92.3%) had low BMD. Lean mass (LM) was positively correlated with BMD in all regions of interest, and the starting age of adult growth hormone (GH) replacement was negatively correlated with the BMD Z-score at the femur neck. In logistic regression analysis, male sex and low LM were related to low BMD. CONCLUSIONS: The iGCTLS had a high prevalence of low BMD. We found that male sex, low LM, and delayed start of adult GH replacement were risk factors for osteoporosis. Therefore, the BMD of all iGCTLS should be evaluated, and if it is low, proper management should be started early.
Authors: L M Wagner; M D Neel; A S Pappo; T E Merchant; C A Poquette; B N Rao; C Rodriguez-Galindo Journal: J Pediatr Hematol Oncol Date: 2001-12 Impact factor: 1.289
Authors: Inge M van der Sluis; Annemieke M Boot; Wim C Hop; Yolanda B De Rijke; Eric P Krenning; Sabine M P F de Muinck Keizer-Schrama Journal: Horm Res Date: 2002
Authors: Isaac Odame; Joann Duckworth; Danielle Talsma; Lesley Beaumont; William Furlong; Colin Webber; Ronald Barr Journal: Pediatr Blood Cancer Date: 2006-03 Impact factor: 3.167
Authors: H L Müller; P Schneider; K Bueb; N Etavard-Gorris; U Gebhardt; R Kolb; N Sörensen Journal: Exp Clin Endocrinol Diabetes Date: 2003-05 Impact factor: 2.949
Authors: Kyung Hee Yi; Jin Soon Hwang; Eun Young Kim; Jun Ah Lee; Dong Ho Kim; Jung Sub Lim Journal: J Bone Miner Metab Date: 2013-07-06 Impact factor: 2.626
Authors: M A H den Hoed; B C Klap; M L te Winkel; R Pieters; M van Waas; S J C M M Neggers; A M Boot; K Blijdorp; W van Dorp; S M F Pluijm; M M van den Heuvel-Eibrink Journal: Osteoporos Int Date: 2014-09-11 Impact factor: 4.507
Authors: Cindy Im; Nan Li; Wonjong Moon; Qi Liu; Lindsay M Morton; Wendy M Leisenring; Rebecca M Howell; Eric J Chow; Charles A Sklar; Carmen L Wilson; Zhaoming Wang; Yadav Sapkota; Wassim Chemaitilly; Kirsten K Ness; Melissa M Hudson; Leslie L Robison; Smita Bhatia; Gregory T Armstrong; Yutaka Yasui Journal: J Bone Miner Res Date: 2020-12-30 Impact factor: 6.741
Authors: Jenneke E van Atteveld; Saskia M F Pluijm; Kirsten K Ness; Melissa M Hudson; Wassim Chemaitilly; Sue C Kaste; Leslie L Robison; Sebastian J C M M Neggers; Yutaka Yasui; Marry M van den Heuvel-Eibrink; Carmen L Wilson Journal: J Clin Oncol Date: 2019-05-31 Impact factor: 50.717
Authors: Mirjana Doknic; Marko Stojanovic; Ivan Soldatovic; Tatjana Milenkovic; Vera Zdravkovic; Maja Jesic; Sladjana Todorovic; Katarina Mitrovic; Rade Vukovic; Dragana Miljic; Dragan Savic; Mihajlo Milicevic; Aleksandar Stanimirovic; Vojislav Bogosavljevic; Sandra Pekic; Emilija Manojlovic-Gacic; Aleksandar Djukic; Danica Grujicic; Milan Petakov Journal: Endocr Connect Date: 2021-08-13 Impact factor: 3.335